MDxHealth SA $MDXH Shares Sold by Delta Investment Management LLC

Delta Investment Management LLC lessened its stake in shares of MDxHealth SA (NASDAQ:MDXH) by 8.9% during the second quarter, Holdings Channel.com reports. The fund owned 173,100 shares of the company’s stock after selling 17,000 shares during the period. Delta Investment Management LLC’s holdings in MDxHealth were worth $383,000 at the end of the most recent reporting period.

Separately, Perkins Capital Management Inc. boosted its holdings in MDxHealth by 20.1% during the first quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company’s stock worth $1,678,000 after buying an additional 198,000 shares in the last quarter.

MDxHealth Price Performance

Shares of NASDAQ:MDXH opened at $4.44 on Monday. The company’s fifty day moving average is $3.97 and its two-hundred day moving average is $2.76. The company has a market cap of $209.96 million, a P/E ratio of -5.05 and a beta of 1.65. MDxHealth SA has a 12-month low of $1.35 and a 12-month high of $4.94. The company has a quick ratio of 1.22, a current ratio of 1.31 and a debt-to-equity ratio of 13.81.

MDxHealth (NASDAQ:MDXH) last issued its earnings results on Tuesday, August 5th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $26.60 million during the quarter, compared to analyst estimates of $26.60 million. MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%. MDxHealth has set its Q2 2025 guidance at -0.150–0.150 EPS. Equities analysts expect that MDxHealth SA will post -1.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on MDXH shares. Craig Hallum started coverage on shares of MDxHealth in a report on Thursday, July 17th. They set a “buy” rating and a $8.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of MDxHealth in a report on Saturday. Finally, Wall Street Zen upgraded shares of MDxHealth to a “hold” rating in a report on Saturday, August 30th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.00.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.